NIKKEI 225
38,839.59 +222.49 (+0.58%) HANG SENG
18,939.58 -256.02 (-1.33%) CRUDE OIL
76.93 -0.64 (-0.83%) GOLD FUTURES
2,374.60 -18.30 (-0.76%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,587.27 -567.19 (-1.03%)
AUPH May 2024 6.000 put
| Previous close | 0.4500 |
| Open | 0.2900 |
| Bid | 0.0000 |
| Ask | 2.6500 |
| Strike | 6.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.1300 - 0.3200 |
| Contract range | N/A |
| Volume | |
| Open interest | 21 |
Business WireAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
ROCKVILLE, Md. & EDMONTON, Alberta, May 14, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program.
Business WireAurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
ROCKVILLE, Md. & EDMONTON, Alberta, May 09, 2024--Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
ZacksHow Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
